Andrew Mortlock

Andrew Mortlock currently serves as the Executive Vice President and Head of Early Development & Translational Science at Astellas Pharma, a position held since July 2023. Prior to this role, Andrew accumulated extensive experience at AstraZeneca from 1992 to April 2023, where contributions included serving as Vice President and Global Franchise Head for PARP1 selective and Ceralasertib, leading late-stage clinical assets in oncology, and overseeing various projects in haematology and small molecule development. Andrew's earlier career also included a post-doctoral position in synthetic organic chemistry at UC Berkeley. Andrew holds an MA and DPhil in Chemistry from the University of Oxford.